Biologics Manufacturing: Is Your Company Ready?

Biologics have enormous potential to drive further growth in the biopharmaceuticals market as interest in therapeutic monoclonal antibodies, recombinant proteins, vaccines, and regenerative medicines is increasing. To take advantage of this growth phase and overcome inherent challenges in new ways, companies must continue to leverage new technology that streamlines front-back manufacturing.

Spotlight

Kymab Ltd

Kymab is discovering and developing fully human monoclonal antibody therapeutics using our pioneering Kymouse™ platform.

OTHER WHITEPAPERS
news image

HIGH THROUGHPUT AAV VIRAL TITERING USING NANOPLATE-BASED DIGITAL PCR

whitePaper | December 22, 2022

Determining the physical titer of viral vectors has typically been accomplished using digital droplet PCR (ddPCR). Droplet-based methods, however, are challenged by matrix effects and long analysis times (up to 7 hours).

Read More
news image

Further Discussion on Plasmids to Establish Release Specifications Using a Risk-Based Approach to Manage Supply

whitePaper | December 6, 2022

BioPhorum’s mission is to create environments where the global biopharmaceutical industry can collaborate and accelerate its rate of progress, for the benefit of all.

Read More
news image

Quality Control Solutions for Cell and Gene Therapy

whitePaper | September 10, 2022

Droplet Digital PCR (ddPCR) provides highly precise and absolute quantification of nucleic acids by counting nucleic acid molecules encapsulated in discrete water-in-oil droplets.

Read More
news image

Biosimilars – commercial best practices in the age of sustainability

whitePaper | November 4, 2019

Revenues from biologics increased by 70% from 2011 to 2016. Biologics account for 20-22% of total pharmaceutical spending. IQVIA estimates US biologics spending will reach $320bn by 2023

Read More
news image

rFC adoption for bacterial endotoxin testing

whitePaper | December 7, 2022

OVER THE LAST 20 years, the worldwide value of traded pharmaceutical goods has grown six‑fold, from $113 billion in 2000 to $629 billion in 2019.1 Yet amid such robust growth comes risk to supply chain security as manufacturers become increasingly dependent on a global network of suppliers

Read More
news image

Genetic insights for biopharmaceuticals: Propelling drug candidates into therapeutic assets

whitePaper | March 9, 2023

For biopharmaceutical and biotechnology companies, innovation is imperative. Economic growth in these industries relies heavily upon investment in product development—perhaps more so than any other industry

Read More

Spotlight

Kymab Ltd

Kymab is discovering and developing fully human monoclonal antibody therapeutics using our pioneering Kymouse™ platform.

Events